Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients

BACKGROUND: In the double-blind, phase 3 PALOMA-3 study, palbociclib–fulvestrant significantly prolonged progression-free survival versus placebo–fulvestrant in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) metastatic breast cancer (MBC) who...

Descripción completa

Detalles Bibliográficos
Autores principales: Masuda, Norikazu, Inoue, Kenichi, Nakamura, Rikiya, Rai, Yoshiaki, Mukai, Hirofumi, Ohno, Shinji, Hara, Fumikata, Mori, Yuko, Hashigaki, Satoshi, Muramatsu, Yasuaki, Nagasawa, Takashi, Umeyama, Yoshiko, Huang, Xin, Iwata, Hiroji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399170/
https://www.ncbi.nlm.nih.gov/pubmed/30392115
http://dx.doi.org/10.1007/s10147-018-1359-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399170/
https://www.ncbi.nlm.nih.gov/pubmed/30392115
http://dx.doi.org/10.1007/s10147-018-1359-3

Ejemplares similares